Stocks and Investing Stocks and Investing
Tue, November 9, 2021
Mon, November 8, 2021

Gena Wang Maintained (BLUE) at Hold with Decreased Target to $13 on, Nov 8th, 2021


Published on 2024-10-27 18:34:11 - WOPRAI, Gena Wang
  Print publication without navigation


Gena Wang of Barclays, Maintained "bluebird bio, Inc." (BLUE) at Hold with Decreased Target from $20 to $13 on, Nov 8th, 2021.

Gena has made no other calls on BLUE in the last 4 months.



There are 3 other peers that have a rating on BLUE. Out of the 3 peers that are also analyzing BLUE, 2 agree with Gena's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • John Newman of "Canaccord Genuity" Downgraded from Strong Buy to Hold and Decreased Target to $20 on, Tuesday, August 10th, 2021
  • Yanan Zhu of "Wells Fargo" Downgraded from Buy to Hold and Decreased Target to $25 on, Tuesday, August 10th, 2021


This is the rating of the analyst that currently disagrees with Gena


  • Difei Yang of "Mizuho" Maintained at Strong Buy with Decreased Target to $23 on, Wednesday, September 22nd, 2021
Contributing Sources